Press Releases

     

Date

 

Company

Finn, Warnke & Gayton

03/17/11

 

Bay State Bedrock Joseph Finn has carved a niche for himself in Massachusetts ABC Cases, Bankruptcy Insider March 17, 2011 pg. 20 - 21

12/08/09

 

Finn, Warnke & Gayton Announces A New Service For Biotechnology Firms - A Platform To Sell Intellectual Property

04/02/09

 

Finn, Warnke & Gayton: Non Legal Estate Wrap-up

03/17/09

 

Assignment for the Benefit of Creditors: Evaluating the Option of an ABC? Boston Bar Event Sponsored By Bankrupcty Law Section

08/22/08

 

Joseph Finn on the ABCs of Biotech Liquidation: Beware of Collusion! by Ryan McBride 8/22/08 Xconomy

02/21/08

 

09/15/99

 

CHANGING DIRECTIONS IN MID-STREAM: LESSONS TO BE LEARNED FROM REPOSITIONING YOUR COMPANY

     

Finn, Warnke & Gayton White Papers

     
   

Some Philosophical Notions On The Problem Of Accounting Principals by Joseph F. Finn, Jr. 1968

    Problem Studied Using Informal Logic System of Philosophy

ActivBiotics Inc.

06/19/08

  ActivBiotics Assignee Issues First Distribution of Cash to Creditors

04/02/08

  ActivBiotics' Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million

03/05/08

 

ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates, on March 14, 2008

02/19/08

 

ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD

01/28/08

  ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates

01/15/08

  ActivBiotics Extends Deadline to March 14, 2008 for the Sale of Proprietary Assets, Including Drug Product Candidates

12/18/07

 

ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates

12/07/07

 

ActivBiotics Inc. Assigns Assets to Joseph F. Finn, Jr. C.P.A. for the Benefit of Creditors

     
     

EPIX Pharmaceuticals

12/08/11

  AFBC EPIX Pharmaceutical Auction for S1P1 Assets - all assets sold

11/29/11

 

AMG 277 Discriminates Against S1P3 Receptor by 50-fold.

11/17/11

  AMG 369 Discriminates Against S1P3 Receptor by 296-Fold

11/08/11

 

S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Target Rationale for S1P1 Agonists Explained.

11/01/11

 

Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale

10/25/11

 

Contractual Agreements Revealed for S1P1 Lead Compounds, AMG 369 and AMG 277, Offered for Sale at a December 8, 2011 Sealed Bid Sale

10/18/11

 

S1P1 Agonists are Currently Indicated For Treatment of Multiple Sclerosis

10/12/11

 

S1P1 Lead Compounds, AMG 369 and AMG 277, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale

10/06/11

 

S1P1 Program Assets Generated by Epix Pharmaceuticals, Inc. and Amgen Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale

06/22/10

  AFBC EPIX Pharmaceuticals Auction - all imaging assets sold

05/21/10

 

Epix Pharmaceuticals, Inc. Announces a Change in the May 28, 2010 Auction Sale of Epix Imaging Agents to June 22, 2010

05/17/10

 

Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent

05/10/10

  EPIX Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent

05/04/10

  EPIX Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent

04/19/10

 

Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent

04/12/10

 

Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of MS-325 MRI Imaging Agent

04/05/10

 

Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of Its MRI Imaging Intellectual Properties

10/22/09

  Joseph F. Finn, Jr., Assignee for the Benefit of Creditors of EPIX Pharmaceuticals, Inc.,Releases Statement Regarding Liquidation Process

10/21/09

  AFBC EPIX Pharmaceuticals auction

10/16/09

 

EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patient

10/01/09

  Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009

09/30/09

  AFBC EPIX Pharmaceuticals auction

09/01/09

 

EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction

08/25/09

  EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction

08/18/09

  Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction

08/13/09

  Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction

08/04/09

 

EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and September 30, 2009 for the Auction Sale of the Intellectual Property

07/22/09

  EPIX Pharmaceuticals Inc., Assigns all Its Assets to Joseph F. Finn Jr., C.P.A. for the Benefit of Its Creditors

07/20/09

  Epix Pharmaceuticals Assigns Assets to Joseph F. Finn, Jr. C.P.A. for the Benefit of Creditors
     
     

n2N Inc.

06/16/08

  Demandware Awarded n2N Commerce’s Assets in Sealed Bid Auction

02/19/08

 

n2N SOFTWARE TO BE AUCTIONED APRIL 11, 2008

     

NMT Medical Inc.

     
06/10/11   Assets Sold
06/01/11  

NMT Medical, Inc. to Sell BioTREK Technology Platform at Its Sealed Bid Sale on Friday, June 10, 2011 at Twelve O'Clock Noon

05/17/11  

NMT Medical, Inc. Adds Intellectual Property to Its Sealed Bid Sale of Friday, June 10, 2011 at Twelve O'Clock Noon

05/10/11

 

NMT Medical, Inc. Sealed Bid Sale of its Intellectual Property to Take Place Friday, June 10, 2011 at Twelve O'Clock Noon

05/02/11

 
4/20/11   NMT Medical Assigns Assets to Joseph F. Finn, Jr. C.P.A. for the Benefit of Creditors
     
     

NoblePeak Vision Corp.

11/05/10

  AFBC NoblePeak Vision Inc. Auction

10/12/10

 

NoblePeak Vision Corp. Offers Patented Technology to Integrate Germanium Photodetectors with Silicon Circuits at the November 5, 2010 Sealed Bid Sale

10/04/10

 

NoblePeak Vision Corp. Offers Patented Technology to Integrate Germanium Photodetectors With Silicon Circuits at the November 5, 2010 Sealed Bid Sale

09/27/10

 

NoblePeak Vision Corp. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors

     

Prospect Therapeutics Inc.

06/29/09   Assets sold
06/22/09   Prospect Therapeutics Inc.'s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers
06/15/09  

Prospect Therapeutics' In Vitro Studies Demonstrate that GCS-100 Drug Binds to and Blocks the Effects of Galectin-3

06/05/09  

Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule

05/26/09   Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
05/19/09   Prospect Therapeutics, Inc.'s GCS-100 Exhibits a Low Toxicity Profile in Cancer Patients
05/12/09  

Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors

05/07/09   Prospect Therapeutics Assigns Assets to Joseph F. Finn, Jr. C.P.A. for the Benefit of Creditors
06/01/09   Interim Phase 2 Results On Prospect Therapeutics' GCS-100 Presented At The 10th International Conference On Malignant Lymphoma
     
     

Source Precision Medicine Inc. D/B/A  SourceMDx

     
04/29/2011  

Assets Sold

04/06/2001  

Source Precision Medicine, Inc., d/b/a Source MDx Announces Source Laboratory Information Management Systems (LIMS), Source Dynamics and Source Primer/Probe Database Will Be Offered for Sale on April 29, 2011

03/29/2011  

Source Precision Medicine, Inc. d/b/a Source MDx Announces 16 Molecular Diagnostic Development Programs Will Be Offered for Sale on April 29, 2011

03/21/2011  

Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011

03/01/11  

Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP

02/25/11

  Source Precision Medicine Inc., D/B/A Assigns Assets to Joseph F. Finn, Jr. C.P.A. for the Benefit of Creditors
     
     

Spherics Inc.

10/10/08

 

Assets sold

09/15/08

 

Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)

09/09/08

 

Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System

09/02/08

 

Spherics, Inc. Offers Once Daily Extended Release Formulation for Sustained and Stable Pramipexole Delivery

08/25/08

 

Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels

08/13/08

 

Spherics, Inc. Successful Bidder May Make NDA Submission

08/04/08

 

Spherics, Inc. Assigns Assets to Joseph F. Finn, Jr., C.P.A.